HEAL Initiative: Sickle Cell Disease Pain Management Trials Utilizing the Pain Management Effectiveness Research Network Cooperative Agreement (UG3/UH3, Clinical Trial Required)
Agency: National Institutes of Health
Assistance Listings
- 93.233 -- National Center on Sleep Disorders Research
- 93.839 -- Blood Diseases and Resources Research
- 93.307 -- Minority Health and Health Disparities Research
- 93.213 -- Research and Training in Complementary and Integrative Health
- 93.350 -- National Center for Advancing Translational Sciences
- 93.840 -- Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders
- 93.838 -- Lung Diseases Research
- 93.313 -- NIH Office of Research on Women's Health
- 93.867 -- Vision Research
- 93.837 -- Cardiovascular Diseases Research
- 93.846 -- Arthritis, Musculoskeletal and Skin Diseases Research
- 93.361 -- Nursing Research
- 93.279 -- Drug Abuse and Addiction Research Programs
Archived opportunityLast Updated: May 13, 2026
View version history on Grants.gov
Description
The purpose of this Funding Opportunity Announcement (FOA) is to solicit cooperative agreement applications to support multisite effectiveness clinical trials of pharmacologic, nonpharmacologic, and/or multicomponent approaches for acute and/or chronic sickle cell disease (SCD) pain management, allowing continued opioid pain management as needed. However, opioid medication use alone should not be the only intervention studied. Trials supported under this initiative may also address the impact of these approaches on related psychological and functional outcomes to support improved overall well-being...
and quality of life. In addition, studies that address stigma, structural health care system, and social factors that may hinder quality comprehensive pain care for patients with SCD are also of interest. Investigators are encouraged to include the collection of well-justified biological markers or psychological processes that have demonstrated that they may mediate pain outcomes. Trials should collect sufficient measures to phenotype participants such as type of pain, variability of pain, co-occurring conditions, and social determinants of health. The studies must address questions within the mission and research interests of the NIH HEAL Initiative and evaluate preventive or treatment strategies or interventions including medications, biologics, procedures, medical and assistive devices and technologies, behavioral interventions, rehabilitation strategies, complementary interventions, integrated approaches, and delivery system strategies in well controlled trials in patients with SCD to manage acute and/or chronic pain.
Eligibility
Eligible applicants
Business
- Small businesses
- For-profit organizations other than small businesses
Government
- City or township governments
- State governments
- Special district governments
- Public and Indian housing authorities
- Federally recognized Native American tribal governments
- County governments
Education
- Public and state institutions of higher education
- Private institutions of higher education
- Independent school districts
Nonprofit
- Nonprofits non-higher education without 501(c)(3)
- Nonprofits non-higher education with 501(c)(3)
- Other Native American tribal organizations
Miscellaneous
- Other
Additional information
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Grantor contact information
Description
NIH OER Webmaster
OERWebmaster03@od.nih.gov
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Documents
No documents are currently available.
Link to additional information
http://grants.nih.gov/grants/guide/rfa-files/RFA-AT-22-005.html
Archived: January 20, 2022
Award
$--
Program Funding
--
Expected awards
$--
Award Minimum
$--
Award Maximum
Funding opportunity number:
RFA-AT-22-005
Cost sharing or matching requirement:
No
Funding instrument type:
Cooperative agreement
Opportunity Category:
Discretionary
Opportunity Category Explanation:
--
Category of Funding Activity:
Education
Health
Category Explanation:
--
History
Version:
1
Posted date:
October 29, 2021
Archive date:
January 20, 2022
